Top Banner
Hiromi Imamichi , Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard A. Lempicki, and H. Clifford Lane. Cryptic transcription of HIV-RNA species from “defective” proviruses: A novel pathway for persistent immune activation in patients with HIV-1 infection and mechanism for persistent seropositivity despite “undetectable” levels of virus NIAID, NIH, DHHS; Leidos Biomedical Research, Inc.; Pacific Biosciences
15

Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

Dec 14, 2015

Download

Documents

Darien Haller
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard A. Lempicki, andH. Clifford Lane.

Cryptic transcription of HIV-RNA species from “defective” proviruses: A novel pathway for persistent immune activation in patients with HIV-1 infection and mechanism for persistent seropositivity despite “undetectable” levels of virus

NIAID, NIH, DHHS; Leidos Biomedical Research, Inc.; Pacific Biosciences

Page 2: Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

The authors declare no competing financial interests.

Conflict of interest

Page 3: Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

Previous observations

Despite years of successful therapy (defined as HIV-RNA levels <50 copies/ml), the majority of HIV-infected patients exhibit persistent seropositivity to HIV-1 and evidence of chronic immune activation.

While plasma HIV-RNA levels are often referred to as “undetectable”, cell-associated proviral DNA can still be detected in circulating PBMCs. Much of this proviral DNA has been characterized as “defective”.

We have recently reported that such “defective” proviral DNA is capable of transcribing RNA. (Imamichi et al., AIDS, 2014;28:1091)

Page 4: Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

Interestingly, in the setting of bone marrow transplantation, a loss of seropositivity has been reported in association with a loss of proviral DNA.

(continued)Previous observations

- Hϋtter et al., NEJM, 2009;360:692- Henrich et al., JID, 2013;207:1694- A patient treated at the NIH Clinical Center (unpublished data)

Page 5: Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

Purpose

Determine whether or not the peripheral blood pool of proviral DNA is capable of being transcribed and translated into viral proteins even if unable to encode an intact virus.

Page 6: Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

Study design

Page 7: Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

Study participants

Pt 1

Pt 2

Pt 3

Pt 4

Pt 5

Pt 6

Pt 7

Yrs. since1st tested

Pos.

12

16

19

15

26

22

20

HIV-RNA(copies/ml)

<50

<50

<40

<50

<40

<40

<40

CD4+

(cells/µl)

796

879

1,061

675

1,142

1,372

1,227

Yrs. ofHIV-RNA

<50

4

4

6

4

6

6

6

ART regimen

3TC+d4T+RTV

FTC+TDF+EFV

3TC+d4T+RTV

3TC+AZT+NFV

FTC+TDF+RTV+ATV

FTC+TDF+NVP

ABC+3TC+EFV

Pt 8 n.a. >500,000 82 --

Page 8: Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

High prevalence of truncated “defective” proviruses in a patient with prolonged viral suppression

Page 9: Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

Clonal expansion of truncated “defective” proviruses

Page 10: Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

Frequencies of proviruses with different lengths

Page 11: Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

The truncated “defective” proviruses are associated with novel RNA transcripts

Page 12: Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

H9 cells infected with HIVMN are capable of expressing HIV-1 proteins in the absence of intact proviruses

Page 13: Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

Summary

Utilizing an LTR to LTR “full-length” PCR, we identified a high prevalence of “defective” proviruses in patients with prolonged viral suppression.

- Are associated with RNA transcription

- Are capable of encoding viral proteins in the absence of an intact virus

- Could be found in cells undergoing clonal expansions and thus were associated with long-term persistence

- Contain large internal deletions

These proviruses:

Page 14: Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

Summary (continued)

These “defective” proviruses:

- Are incapable of producing intact viruses

- Can still inflict harm by producing foreign proteins or by recombining to form intact viruses

These results may help to explain:

- The persistent seropositivity in most patients with controlled HIV-1 infection

- The sero-reversions seen in a limited number of patients following transplantation

Strategies directed toward “curing” HIV-1 need to include approaches designed to eliminate cells harboring such proviruses

- The persistent immune activation in patients with HIV-RNA levels <50 copies/ml

- The delayed time to rebound in the Mississippi baby

Page 15: Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

AcknowledgementsPacific Biosciences

Yan GuoLori Dodd

Colleen Ludka

Michael Brown

Ellen Paxinos

NIAID, NIH

Cliff Lane

Catherine A. Rehm

Colleen Hadigan

Leidos Biomedical Research

Richard Lempicki

Da Wei Huang

Joseph Adelsberger

Tomozumi Imamichi

Robin Dewar

Clinical and Laboratory staffat the NIAID/CCMD clinic andLeidos Biomedical Research

The study participants

Dun Liang